More Than Tablets and Infusions: China’s Specialized Drug Formulations Are Rapidly Evolving

By:DengYue International Business Division

For a long time, the core logic of pharmaceutical innovation was relatively straightforward: identify new mechanisms of action, discover new molecular targets, and improve therapeutic efficacy. In recent years, however, as innovative drug development has entered a more mature stage, relying solely on new drug molecules has become increasingly insufficient for creating meaningful differentiation.

Across many therapeutic areas, the drug itself is no longer the only factor determining treatment outcomes.

The same drug may produce very different clinical results depending on how it enters the body. Some drugs are easily degraded after oral administration, some demonstrate strong efficacy but are limited by toxicity concerns, while others struggle to reach target tissues efficiently, reducing overall therapeutic performance.

As a result, a clear trend is emerging in modern pharmaceutical research:

Competition is no longer defined only by what the drug is, but increasingly by how the drug enters the body.

Drug Delivery Systems (DDS) are becoming a major focus of global innovation. The development of specialized formulations—including liposomes, nanomedicine delivery systems, microneedles, transdermal technologies, sustained-release implants, and inhalation formulations—is gradually changing traditional treatment approaches.

Beyond innovative drug discovery itself, China has also accelerated investments in formulation platforms and drug delivery technologies in recent years. As a platform closely following Chinese innovative medicines and global healthcare trends, DengYueMed continues to monitor advances in drug delivery systems, novel formulation technologies, and pharmaceutical innovation in China, helping international patients and industry partners understand emerging therapeutic developments.

Why Drug Formulations Are Becoming a New Competitive Dimension

Once administered, drugs undergo a series of biological processes, including absorption, distribution, metabolism, and elimination.

Even when a drug molecule demonstrates strong anti-cancer or antiviral activity, its clinical effectiveness may still be limited if it cannot efficiently reach the intended target site.

Traditional formulations commonly include:

● Conventional oral tablets

● Capsules

● Intravenous infusions

● Standard injectable formulations

However, conventional delivery approaches also face several practical limitations:

● Drug degradation in the gastrointestinal tract

● Limited efficiency in reaching disease sites

● Greater systemic toxicity exposure

● Frequent administration requirements

● Reduced patient adherence

The purpose of specialized formulations is fundamentally to optimize what happens after a drug enters the body.

The goals extend beyond improving efficacy and may include:

● Improving drug targeting capability

● Reducing toxicity

● Extending therapeutic duration

● Enhancing patient experience

● Optimizing long-term disease management

Liposomal Drugs: Changing How Drugs Travel Through the Body

Liposomes are among the most established specialized formulation technologies currently in use.

Structurally, liposomes are small vesicles composed of phospholipid bilayers resembling cellular membranes. Drug molecules can be encapsulated inside these structures, altering their distribution behavior within the body.

One of the earliest reasons liposomal technologies gained significant attention was their potential to reduce drug toxicity.

Representative products include:

● Doxil

● Vyxeos

● AmBisome

Traditional doxorubicin, for example, has long demonstrated strong anti-cancer activity but may be associated with cumulative cardiac toxicity during prolonged treatment. Liposomal doxorubicin changes the drug's distribution profile, reducing exposure in normal tissues while improving accumulation within tumor environments.

In recent years, liposomal technologies have expanded into additional applications:

● Oncology therapies

● Anti-infective drugs

● RNA therapeutics

● Vaccine platforms

The development of mRNA vaccines has further increased global interest in lipid-based delivery technologies.

Nanomedicine: Improving Precision Drug Delivery

Nanomedicine has become one of the fastest-growing areas among specialized formulations.

Nanoparticle delivery systems generally range from tens to hundreds of nanometers in size and may take advantage of unique tumor vascular characteristics to increase drug accumulation at target sites.

Common delivery platforms include:

● Polymer nanoparticles

● Lipid nanoparticles (LNPs)

● Albumin-based nanoparticles

● Inorganic nanomaterials

A representative product is:

● Abraxane

Compared with conventional paclitaxel formulations, Abraxane utilizes albumin nanoparticle technology to improve solubility and delivery while reducing certain solvent-related toxicities.

More recently, lipid nanoparticle platforms have also become critical tools for nucleic acid therapeutics, including:

● mRNA therapies

● siRNA drugs

● Gene-editing delivery systems

As gene therapies and RNA medicines continue expanding, the importance of nanotechnology-based delivery systems is expected to grow further.

Microneedle Technology: Moving From Injections Toward Nearly Painless Drug Administration

Microneedles have attracted significant attention in recent years, although many people mistakenly assume they are simply "smaller needles."

In reality, microneedles represent a new drug delivery platform.

Traditional subcutaneous injections penetrate relatively deep tissue layers and may involve pain, irritation, and procedural requirements. Microneedles, by contrast, generally penetrate only a few hundred micrometers into the skin surface.

Since most pain receptors are located deeper within tissues, patients may experience substantially reduced discomfort.

In practice, microneedle administration functions more like a patch:

Patients place the microneedle patch on the skin for several minutes to several hours.

The microneedle structures then gradually dissolve or release medication before being removed.

Key advantages include:

● Lower pain levels

● Ease of administration

● Potential for self-use

● Improved bioavailability

Current research applications include:

● Vaccine delivery

● Insulin administration

● Oncology therapeutics

● Biologic drug delivery

In the future, some injectable medications may potentially transition toward patch-based administration.

Transdermal Delivery: Moving Beyond Gastrointestinal Dependence

Transdermal drug delivery is not a new concept, but its applications continue expanding.

Representative products include:

● Duragesic

● Nicotinell

● Exelon Patch

Its major advantages include:

● Avoiding gastrointestinal degradation

● Bypassing first-pass liver metabolism

● Sustained drug release

● Reduced dosing frequency

For patients requiring long-term treatment, transdermal technologies may provide more stable drug exposure.

Sustained-Release Implants: Extending Treatment From Days to Months or Years

Repeated treatment can become a significant burden for patients receiving long-term therapy.

As a result, sustained-release implant technologies have attracted increasing attention.

The principle is relatively straightforward: medications are incorporated into biodegradable materials or implant systems that continuously release drugs over extended periods.

Representative products include:

● Zoladex

● Ozurdex

Applications include:

● Cancer treatment

● Ophthalmology

● Hormonal therapy

● Pain management

For some patients, a single implantation procedure may provide therapeutic coverage for several months.

Administration differs substantially from conventional oral medication.

For example:

In prostate cancer treatment, certain hormonal therapies may be delivered through subcutaneous implants that continuously release medication for several months.

In ophthalmology, implants may be inserted directly into the eye to provide long-term drug release.

For many patients, the primary benefit is not necessarily increased efficacy, but a significant reduction in treatment frequency:

Weekly or monthly treatments gradually become:

Single procedure → Continuous drug release over months

However, implant technologies are not suitable for every drug.

Inhalation Formulations: Expanding Beyond Respiratory Diseases

When inhaled medications are mentioned, most people immediately think of asthma inhalers.

From a drug delivery perspective, however, the lungs possess unique physiological advantages:

● Surface area approaching 70–100 square meters

● Dense capillary networks

● Rapid absorption capability

● Ability to bypass first-pass liver metabolism

As a result, inhalation technologies are increasingly expanding beyond respiratory medicine.

Representative products include:

● Symbicort

● Spiriva

Emerging applications include:

● Inhaled insulin

● Cancer therapies

● Vaccine delivery

● Systemic disease treatment

Because the lungs provide extensive surface area and abundant blood supply, they are increasingly being explored as a potential route for systemic drug delivery.

Future inhalation technologies may extend well beyond local treatment applications.

China's Development of Specialized Formulations Is Accelerating

Specialized formulation technologies were historically dominated by pharmaceutical companies in Europe and the United States. In recent years, however, Chinese companies have increasingly expanded investment in this area.

Current areas of focus include:

● Liposomal platforms

● Nanomedicine

● Microsphere technologies

● Long-acting formulations

● RNA delivery platforms

● Microneedle systems

As pharmaceutical innovation advances further, more companies recognize that drug molecules alone may no longer be sufficient to establish long-term competitive advantages.

Drug delivery platforms themselves are increasingly becoming critical technological barriers.

Conclusion

Modern pharmaceutical development is gradually shifting from simply discovering new drugs toward optimizing how therapies function within the body.

Specialized formulations are not designed to replace traditional therapies but to improve the pathway and efficiency through which drugs reach their targets.

In the future, differences between therapies may increasingly depend not only on the drug itself, but also on how effectively, precisely, and conveniently it can deliver treatment to patients.

DengYue continues to follow developments in Chinese innovative medicines, advanced drug delivery systems, and emerging pharmaceutical technologies, providing international patients and industry partners with information support and cross-border healthcare resource connections.

This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Treatment decisions should always be made in consultation with qualified healthcare professionals.